In Vivo Characterization of Synthetic Cannabidiol Analogs for Seizure Suppression in Zebrafish

Abstract Epilepsy affects over 70 million people worldwide, nearly 20% of whom experience pharmacoresistant forms, particularly in pediatric populations. Cannabidiol (CBD) shows promise for the treatment of neurological disorders, including refractory epilepsy, but its low potency necessitates high dosing, leading to side effects that include drowsiness, gastric issues, and potential hepatotoxicity. Regulatory barriers, high cost, abuse liability, and the poor sustainability of hemp cultivation are further drawbacks to CBD use. In an effort to circumvent these issues, a series of